N/A N=312 Pertussis Infection in Adolescents and Adults With Prolonged Cough
Pertussis
Primary: Serological Evidence of Pertussis Infection — 50; 74; 84; 26 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,830 Seroepidemiological Study of Pertussis and Other Infectious Diseases
Pertussis Infection
Primary: IgG — 1.254; 1.258 EU/mL(log transformed)
Phase 2 N=53 Pertussis Challenge Study in Adults Vaccinated With BPZE1
Pertussis/Whooping Cough · Bordetella Pertussis, Whooping Cough
Primary: Number of Participants Colonized Following Virulent Challenge — 8; 12 Participants
Early Phase 1 N=42 Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women
Pertussis · Pregnancy Related
Primary: The Seroprevalence of Anti-pertussis Toxin Antibodies (Anti-PT IgG) in Pregnant Thai Women — 43 Participants
N/A N=290 Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States
Whooping Cough
Primary: Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During Third Trimester of Pregnancy) or Not Exposed to Any…
Phase 1 N=54 Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
Pertussis · Whooping Cough
Primary: The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events…
N/A N=86 Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure
Pertussis
Primary: Evidence of Pertussis Infection in Each PEP Arm, Defined Using Clinical, Microbiologic, or Serologic Criteria. — 6; 1 participants
N/A N=12,760 Increasing Influenza and Tdap Vaccination of Pregnant Women
Immunization; Infection · Pregnancy Related
Primary: Rate of Influenza Vaccination — 2382; 2496 participants
Phase 2 N=366 Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
Bordetella Pertussis, Whooping Cough
Primary: Geometric Mean Fold Rise (GMFR) of Mucosal Immunogenicity S-IgA Against Whole Cell Extract at Day 29 — 3.8; 3.5; 1.2 Fold Rise
N/A N=2,000 A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary
Pertussis · Pertussis Vaccines
Primary: Number of Seropositive Subjects in Terms of Anti-pertussis Toxin (Anti-PT) Concentrations — 295 Participants
Phase 2 N=300 Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults
Pertussis · Whooping Cough
Primary: Number of Participants With Nasal Mucosal Seroconversion (Immunoglobulin A [IgA]) — 79; 89; 38; 42 Participants
Phase 1 N=16 Inhaled Tobramycin in BPD
Bronchopulmonary Dysplasia
Primary: Elevated Serum Tobramycin Trough or Creatinine or Severe Adverse Event — 0; 0; 0; 1 Participants
N/A N=48 Cohort Isolation and Cross-infection in Bronchiolitis
Bronchiolitis
Primary: Duration of Hospital Stay — 3.9; 2.1 days
Phase 4 N=321 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Healthy Subjects
Primary: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series — 100.0…
Phase 1 N=10 Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex
Cystic Fibrosis · Burkholderia Cepacia Infection
Primary: The Change in Sputum Density of BCC in Colony Forming Units (CFUs)/ml From Day 0 to Day 28 of TIP Treatment. — -1.4 CFU/ml log10
Phase 4 N=215 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Pertussis · Diphtheria · Tetanus
Primary: Number of Participants Reporting a Solicited Local or Systemic Reaction Post-Vaccination With Either REPEVAX® or COVAXIS® Vaccine — 89; 87; 85; 87 Participants
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units
Phase 1 N=420 Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
Pertussis · Whooping Cough · Tetanus
Primary: The Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine — 30; 33; 32; 35…
Phase 4 N=81 Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
Pregnancy
Primary: Percentage of Participants With Injection-site Reactions Post Tdap and IIV4 Administration — 47.5; 48.6; 37.5; 45.9 percentage of participants
Phase 3 N=1,042 Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants Who Achieved Seroprotection at Baseline and 30 Days Post-vaccination for Diphtheria and Tetanus at ≥ 0.1 IU/mL Level — 65; 69; 100; 100…
Phase 3 N=447 Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects
Diphtheria-Tetanus-acellular Pertussis Vaccines
Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D). — 437; 1 Participants
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Phase 4 N=1,561 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
Pertussis · Tetanus · Diphtheria
Primary: Geometric Mean Titers (GMTs) of Tetanus, Diphtheria, and Pertussis Antibodies Pre- and Post-Vaccination With ADACEL® or DECAVAC® Vaccine — 0.501; 0.451; 8.43; 7.23 Titers
Phase 2 N=60 Preschool Wheeze: Inflammation/Infection Guided Management
Asthma
Primary: Number of Unscheduled Healthcare Visits (UHCV) — 0.5; 0.5 number of visits — p=0.05
Phase 1 N=315 Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
Pertussis
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens at Day 1. — 28; 31; 48; 18 IU/mL
Phase 2 N=304 Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Cystic Fibrosis · Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization — 24; 26; 29; 21 number of participants — p=0.86
Phase 2 N=217 The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
COVID-19
Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…
Phase 4 N=11 Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
Pulmonary Infections
Primary: Percent Reduction in Oxygen Requirement From Baseline — 5.4; 16.5 percentage FiO2
Phase 3 N=754 Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
Hepatitis B · Pertussis
Primary: Percentage of Participants Responding to Hepatitis B Surface Antigen (HBsAg) — 70.16; 82.01; 65.75; 83.68 Percentage of Participants
Phase 2 N=107 Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Non-cystic Fibrosis Bronchiectasis
Primary: Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs) — 6.80; 7.67; 6.10; 6.98 log10 CFUs